Mouse Anti-SIV gag p27 Monoclonal antibody, clone LL75

SIV p27 is a structural protein widely used in the study of simian immunodeficiency virus (SIV), which serves as a non-human primate model for human immunodeficiency virus (HIV). By studying SIV's infection mechanisms and immune responses, researchers can gain valuable insights that inform the development of AIDS vaccines. p27 is a core component of the SIV capsid protein, playing a critical role in the assembly, stability, and function of viral particles. As a result, it holds significant importance in vaccine research. In recent years, increasing attention has been paid to the role of SIV p27 as an antigen in vaccine development, particularly its involvement in mucosal immune responses in the gut. Gut-targeted immune responses are crucial in preventing the spread of HIV/SIV, as the gut is one of the key sites of early viral infection. Therefore, vaccines that effectively activate immune responses in the gut mucosa are vital. One study evaluated the capacity of an oral vaccine expressing SIV p27 through Clostridium perfringens (Cp-p27) to initiate multifunctional immune responses in a mouse model. The study found that Cp-p27, when delivered via the gut, effectively activated immune cells in the mouse intestines, particularly dendritic cells in Peyer's patches. These dendritic cells matured after exposure to Cp-p27 and were able to stimulate p27-specific IFN-γ secretion, indicating the potential to initiate specific cellular immune responses. Additionally, the study noted that the combination of oral Cp-p27 with an adenovirus-based vaccine expressing SIV p27 (Ad-p27) enhanced immune responses, especially by inducing multifunctional CD8+ T-cell responses in the gut.

Controlling SIV infection is still quite difficult from a systemic immunological standpoint, especially when it comes to removing viral reservoirs and the enduring nature of chronic infection. Antiretroviral therapy (ART) can effectively suppress HIV/SIV replication; however, it is not a 100% effective means of eradicating the infection, according to some research. After lentivirus infections, viral reservoirs continue to exist, resulting in a chronic and irreversible infection. Rhesus macaques (RMs) can have SIV infection under control thanks to recent experiments employing cytomegalovirus (RhCMV) vectors, especially when it comes to the highly pathogenic strain SIVmac239. A fraction of rhesus macaques was discovered to be able to control SIV infection following vaccination using RhCMV/SIV vectors producing SIV proteins, leading to the absence of detectable virus in the blood and tissues. The CMV vector-induced immune surveillance of effector memory T cells was intimately linked to this immunological control. Understanding the processes of HIV and SIV infection centers on the regulation of the immune system and host interactions. SIV is a virus that infects non-human primate species chronically and has a highly diverse range of intricate infection mechanisms. SIV infection is often non-pathogenic in natural hosts, in contrast to HIV infection in humans. For instance, SIV infection in chimpanzees and sooty mangabey monkeys does not lead to significant immune dysfunction or disease. This phenomenon is related to the long-term co-evolution between SIV and its natural hosts, suggesting that host-virus co-adaptation plays a crucial role in lentivirus infections.

In rhesus macaques, SIV infection provides an ideal model for studying AIDS. SIVmac251 and SIVmac239 are the most commonly used SIV strains for rhesus macaque infection, capable of causing high levels of viral replication and rapid CD4+ T cell loss, leading to AIDS development in a relatively short time. These models not only aid in understanding HIV transmission and pathogenesis but also provide a foundation for developing potential anti-AIDS vaccines and treatments. SIV belongs to the retrovirus family, specifically the Orthoretrovirinae subfamily and the lentivirus genus, sharing similar viral structures and replication mechanisms with HIV. SIV contains a double-stranded positive-sense single-stranded RNA genome, protected by a conical capsid composed of capsid proteins. The capsid is surrounded by a spherical envelope embedded with multiple glycoproteins. These glycoproteins are essential for viral entry into host cells, as they mediate the fusion and entry of the virus by binding to receptors on the host cell surface. During this process, SIV core proteins, such as p27, play an important role in maintaining the integrity of viral particles and promoting their replication inside host cells. The application of SIV p27 in vaccine research extends beyond its basic function as a structural protein. By targeting immune responses to p27, scientists hope to effectively control viral replication and prevent its spread. In this context, the importance of mucosal immunity in the gut has been emphasized again. Since HIV/SIV is often transmitted through mucosal pathways during the early stages of infection, quickly activating immune defenses at these sites is critical. p27, as a potential vaccine antigen, has demonstrated promising immunogenicity in several animal studies, particularly in the induction of multifunctional T cells, which are crucial for controlling chronic viral infections. Overall, research on SIV p27 not only provides new perspectives for understanding the infection mechanisms of SIV and HIV but also offers possible pathways for future AIDS vaccine development. By combining systemic and mucosal immune strategies, scientists aim to design vaccines capable of providing long-term protection and further controlling or even eliminating viral reservoirs within the body. In this process, p27, as one of the core antigens, holds great promise for application.

Anti-SIV gag p27 antibody
Anti-simian immunodeficiency virus p27 antibody
SIV p27 monoclonal antibody
LL75 antibody